Table 1.

Percent change in PGE₂ by the treatment of the inhibitors targeting Arachidonic acid cascade, ERK MAPK pathway, and p38 and JNK MAPK pathway.

Pathway	Target	Compound	Percent change (%)
Arachidonic acid cascade (FDR = 0.086)	COX-1	Sulindac sulphide	−89.1
	COX-1	Valeryl salicylate	−55.4
	COX-2	NS-398	−90.2
	COX	Sodium salicylate	−8.7
	PLA2	cPLA2inhibitor	−78.9
	PLA2	OBAA	−29.9
	lipoxygenase	Nordihydroguaiaretic acid (NDGA)	−28.7
	12, 15-lipoxygenase	ETYA	−73.4
	12-lipoxygenase	Baicalein	−68.0
MAPK (ERK) pathway (FDR = 0.067)	MEK	PD 98059	−76.3
	MEK	U0126	−69.1
	MAPK	ERK inhibitor II	−50.0
	MEK	MEK inhibitor I	−78.2
	Raf	RAF1 kinase inhibitor I	−72.5
	Raf	ZM 336372	−48.2
	Tpl2	Tpl2 kinase inhibitor	26.2
	BRAF	Vemurafenib	−69.1
MAPK (p38 and JNK) pathway (FDR = 0.067)	JNK	SP600125	−53.9
	p38 (MAPK)	PD169316	−82.0
	p38 (MAPK)	SB 203580	−73.0
	JNK	JNK inhibitor VIII	−12.4
	p38	SB202190	−68.3
	p38	SB239063	−57.6